非免疫球蛋白::MYC融合的弥漫大B细胞淋巴瘤具有可变基因组构型与MYC反式激活潜能
研究分析186例伴MYC易位的弥漫大B细胞淋巴瘤(DLBCL),包括32例三打击、75例MYC/BCL2双打击和26例MYC/BCL6双打击。非免疫球蛋白::MYC融合者MYC蛋白表达可变,部分病例未见明显使MYC反式激活的基因组构型,而典型启动子替换或IGH超级增强子并置见于其余病例。
要点
- 186例伴MYC易位DLBCL中,MYC/BCL6融合见于59%的三打击和27%的MYC/BCL6双打击。
- 免疫球蛋白::MYC融合者MYC蛋白表达一致增高,非免疫球蛋白::MYC融合者表达可变。
- 4例非免疫球蛋白::MYC融合中3例未见明显使MYC反式激活的基因组构型。
核心结论
- 非免疫球蛋白::MYC融合的DLBCL具有可变基因组构型和MYC反式激活潜能,可能解释伴MYC易位DLBCL中MYC表达的可变性,并对常规评估有实践意义。
研究设计与样本
- 研究纳入186例伴MYC易位的DLBCL,包括32例MYC/BCL2/BCL6三打击、75例MYC/BCL2双打击和26例MYC/BCL6双打击。
- 采用FISH检测融合,靶向NGS分析突变谱和LymphGen遗传亚型,基于TLC的NGS对8例进行易位断点分析。
主要发现
- FISH显示MYC/BCL6融合见于59%的MYC/BCL2/BCL6三打击和27%的MYC/BCL6双打击。
- 靶向NGS显示MYC/BCL2/BCL6三打击与MYC/BCL2双打击的突变谱和LymphGen遗传亚型相似,而MYC/BCL6双打击的LymphGen亚型可变。
- 免疫球蛋白::MYC融合者MYC蛋白表达一致增高,非免疫球蛋白::MYC融合者(包括MYC/BCL6融合)表达可变。
- 基于TLC的NGS断点分析8例,4例非免疫球蛋白::MYC融合中3例未见明显使MYC反式激活的基因组构型,其余病例见典型启动子替换或IGH超级增强子并置。
关键数值与推荐
- MYC易位见于8-14%的DLBCL,可合并BCL2和/或BCL6易位,称为双打击或三打击。
- 仅40-50%伴MYC易位的DLBCL显示高MYC蛋白表达(>70%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MYC translocation occurs in 8-14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL-MYC/BCL2-DH/TH are largely germinal centre B-cell like subtype, but show variable clinical outcome, with IG::MYC fusion significantly associated with inferior survival. While DLBCL-MYC/BCL6-DH are variable in their cell-of-origin subtypes and clinical outcome. Intriguingly, only 40-50% of DLBCL with MYC translocation show high MYC protein expression (>70%). We studied 186 DLBCLs with MYC translocation including 32 MYC/BCL2/BCL6-TH, 75 MYC/BCL2-DH and 26 MYC/BCL6-DH. FISH revealed a MYC/BCL6 fusion in 59% of DLBCL-MYC/BCL2/BCL6-TH and 27% of DLBCL-MYC/BCL6-DH. Targeted NGS showed a similar mutation profile and LymphGen genetic subtype between DLBCL-MYC/BCL2/BCL6-TH and DLBCL-MYC/BCL2-DH, but variable LymphGen subtypes among DLBCL-MYC/BCL6-DH. MYC protein expression is uniformly high in DLBCL with IG::MYC, but variable in those with non-IG::MYC including MYC/BCL6-fusion. Translocation breakpoint analyses of 8 cases by TLC-based NGS showed no obvious genomic configuration that enables MYC transactivation in 3 of the 4 cases with non-IG::MYC, while a typical promoter substitution or IGH super enhancer juxtaposition in the remaining cases. The findings potentially explain variable MYC expression in DLBCL with MYC translocation, and also bear practical implications in its routine assessment.
引用
- Zhang C, Stelloo E, Barrans S, et al. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential. Leukemia. 2024. PMID: 38184753. doi:10.1038/s41375-023-02134-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。